Efficacy and Safety of the Anti-mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's Disease.

Vermeire, Séverine; Danese, Silvio; J Sandborn, William; Schreiber, Stefan; Hanauer, Stephen; D'Haens, Geert; Nagy, Peter; Thakur, Manoj; Bliss, Caleb; Cataldi, Fabio; Goetsch, Martina; J Gorelick, Kenneth; Reinisch, Walter

doi:10.1093/ecco-jcc/jjad199

Public

Efficacy and Safety of the Anti-mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's Disease.

Shared by NobleBlocks on May 31, 2024 • 12:00 AM UTC

Authors:

Séverine Vermeire

Silvio Danese

William J Sandborn

Abstract

BACKGROUND AND AIMS: Ontamalimab is a fully human immunoglobulin G2 monoclonal antibody against mucosal addressin cell adhesion molecule-1, developed as treatment for inflammatory bowel disease. METHODS: Six phase 3, multicentre, randomised, double-blind, placebo-controlled clinical trials compared ...

Subject

Biomarkers

clinical trials

endoscopy

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!